- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
CagriSema Shows Significant Weight Loss and Improved Physical Function in REDEFINE 1 Trial

"Obesity is a chronic disease, and people respond to treatment differently and over different timeframes," said Martin Holst Lange, executive vice president, chief scientific officer and head of Research & Development at Novo. "That is why we continue to study the REDEFINE 1 data in greater depth. In this post hoc analysis, most people treated with CagriSema 2.4 mg / 2.4 mg were early responders, meaning they lost at least 5% of their body weight within the first 8 weeks of treatment. Together with the patient-reported physical function results, this research adds to the growing evidence base from the REDEFINE clinical program."
Early response and weight loss trajectories (post hoc analysis)
In this post hoc analysis, 67.8% of CagriSema-treated participants were early responders (at least 5% weight loss at week 8). Observed mean weight loss at week 68 was 25.4% among early responders. Among delayed responders, observed mean weight loss at week 68 was 17.8%.‡ Women were more likely to be early responders than delayed responders (71.8% vs 59.5%).
Weight loss by early response status with CagriSema 2.4 mg / 2.4 mg in REDEFINE 1 (post hoc analysis; observed data).
| Outcome | Early responders (n=1,367) | Delayed responders (n=649) |
| Mean weight loss at week 8 | 7.80% | 3.40% |
| Mean weight loss at week 68 | 25.40% | 17.80% |
| Achieved ≥20% weight loss at week 68 | 73.30% | 37.20% |
| Achieved ≥15% to <20% weight loss at week 68 | 16.10% | 23.80% |
| Achieved ≥10% to <15% weight loss at week 68 | 7.90% | 21.30% |
| Achieved ≥5% to <10% weight loss at week 68 | 2.50% | 14.00% |
| Achieved <5% weight loss at week 68 | 0.30% | 3.60% |
Early responders: ≥5% weight loss at week 8; delayed responders: <5% weight loss at week 8. Weight loss categories at week 68 are mutually exclusive.
Observed data from the on-treatment period; post hoc analysis, hypothesis-generating.
"In clinical practice, it can be hard to know early on how an individual patient will respond to treatment," said Dr. W. Timothy Garvey, Department of Nutrition Sciences, University of Alabama at Birmingham, and author of the REDEFINE 1 early response analysis. "This post hoc analysis shows that people treated with CagriSema 2.4 mg / 2.4 mg experienced different weight loss trajectories, including onset of response to treatment. These values are hypothesis-generating, and they are not the basis for changing clinical decision-making."
Patient-reported physical and psychosocial function
The Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT), used in the REDEFINE 1 analysis, is a validated questionnaire used to assess how weight affects physical function, such as the ability to carry out everyday physical activities, and psychosocial function, such as self-esteem and comfort in social situations, including whether changes are meaningful to the individual.2
At week 68, 73.1% of adults treated with CagriSema 2.4 mg / 2.4 mg reported a meaningful within-person change in physical function vs 49.1% with placebo (post hoc analysis; efficacy estimand,* which assumes all participants adhered to treatment).2 In these post hoc analyses, 69.0% vs 42.1% reported a meaningful within-person change in psychosocial function, and the proportion reporting meaningful within-person change in physical function was significantly greater with CagriSema than with placebo from week 8 through week 68.2
Proportion of adults achieving a meaningful within-person change in IWQOL-Lite-CT scores at week 68 in REDEFINE 1 (post hoc analyses; efficacy estimand*)2
"In clinical practice, it can be hard to know early on how an individual patient will respond to treatment," said Dr. W. Timothy Garvey, Department of Nutrition Sciences, University of Alabama at Birmingham, and author of the REDEFINE 1 early response analysis. "This post hoc analysis shows that people treated with CagriSema 2.4 mg / 2.4 mg experienced different weight loss trajectories, including onset of response to treatment. These values are hypothesis-generating, and they are not the basis for changing clinical decision-making."
Patient-reported physical and psychosocial function
The Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT), used in the REDEFINE 1 analysis, is a validated questionnaire used to assess how weight affects physical function, such as the ability to carry out everyday physical activities, and psychosocial function, such as self-esteem and comfort in social situations, including whether changes are meaningful to the individual.
At week 68, 73.1% of adults treated with CagriSema 2.4 mg / 2.4 mg reported a meaningful within-person change in physical function vs 49.1% with placebo (post hoc analysis; efficacy estimand,* which assumes all participants adhered to treatment).2 In these post hoc analyses, 69.0% vs 42.1% reported a meaningful within-person change in psychosocial function, and the proportion reporting meaningful within-person change in physical function was significantly greater with CagriSema than with placebo from week 8 through week 68.
Proportion of adults achieving a meaningful within-person change in IWQOL-Lite-CT scores at week 68 in REDEFINE 1 (post hoc analyses; efficacy estimand*)
| Outcome at week 68 | CagriSema 2.4 mg / 2.4 mg (n=2,108) | Placebo (n=705) | Estimated treatment difference (95% CI) |
| Physical Function score | 73.1 % | 49.1 % | 24.1% (19.5, 28.7) |
| Physical score | 73.4 % | 50.1 % | 23.3% (18.7, 27.9) |
| Psychosocial score | 69.0 % | 42.1 % | 26.9% (22.5, 31.4) |
| Total score | 69.1 % | 40.4 % | 28.7% (24.2, 33.2) |
*Efficacy estimand: treatment effect if all participants adhered to treatment.
Meaningful within-person change thresholds: 14.6 points (Physical Function), 13.5 points (Physical), 16.2 points (Psychosocial) and 16.6 points (Total).2
"Obesity goes far beyond the scale; my patients are more concerned with how weight affects their ability to move comfortably and participate confidently in everyday life," said Dr. Domenica Rubino, Washington Center for Weight Management and Research, co-author of the REDEFINE 1 physical and psychosocial function analysis. "In this post hoc analysis of REDEFINE 1, 73.1% of people treated with CagriSema 2.4 mg / 2.4 mg reported a meaningful improvement in physical function at week 68, compared with 49.1% of those receiving placebo. Additional post hoc analyses suggest these improvements may begin early in treatment, which warrants further study."
In the REDEFINE 1 trial, discontinuation due to adverse events occurred in 5.9% of participants receiving CagriSema versus 3.5% with placebo.3 Adverse events were mainly gastrointestinal (79.6% in the CagriSema group vs 39.9% with placebo) including nausea (55% vs 12.6%), constipation (30.7% vs 11.6%), vomiting (26.1% vs 4.1%) and were mostly transient and mild-to-moderate in severity.
Novo filed a New Drug Application with the U.S. Food and Drug Administration in December 2025 for CagriSema 2.4 mg / 2.4 mg for weight management. A decision is expected in Q4 2026. CagriSema is not approved for use in the United States. Safety and efficacy are not established. There is no guarantee that this investigational medicine will become commercially available for the uses under clinical investigation.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

